Skip to content
Vivanza Biosciences logo

Vivanza Biosciences

530057 BSE
₹1.36

Close ·

P/E
Not meaningful: last twelve months’ earnings are mostly a one-off item
View as Markdown
MCP
Close 4 Nov 2026 ₹1.36 −0.61 −31.0% 1Y
Start ₹1.97

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
6.11%
Debt to Equity
2.50
EPS (TTM)
₹0.12
Book Value
₹1.09
Market Cap
—
P/E (TTM)
Not meaningful: last twelve months’ earnings are mostly a one-off item
P/B
1.25
ROE
9.38%
Dividend Yield
0.00%
EBITDA
₹80.00 L
52W High
₹2.72
52W Low
₹1.30

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 100/100

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
52
Average
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
13
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Debtor days have improved from 196 to 39.0 days.

Weaknesses

4
  • Promoter holding is low: 20.0%
  • Company has a low return on equity of 2.11% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -27.3%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1252
OscillatorsNeutral252
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
34.07
Neutral
MACD (12,26,9)
−0.09
Bearish
SMA (50)
1.70
Bearish
SMA (200)
1.88
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YZero base
5Y+63.26%
3Y+86.09%
1YTiny base
TTM+735.20%

Net profit

Net profit growth by window
10YZero base
5YZero base
3Y−100.00%
1YLoss narrowed by ₹1 Cr
TTMTurned to profit

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YOutflow unchanged
3YOutflow widened by ₹2 Cr
1YOutflow widened by ₹1 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5Y+0.86 pp
3Y−4.70 pp
1Y+0.86 pp
TTM+4.54 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹3.00 Cr
Mar 2018₹6.00 Cr
Mar 2019₹3.00 Cr
Mar 2020₹10.00 Cr
Mar 2021₹10.00 Cr
Mar 2022₹10.00 Cr
Mar 2023₹18.00 Cr
Mar 2024₹28.00 Cr
Mar 2025₹7.00 Cr
Mar 2026₹116 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹1.00 Cr
Mar 2024₹1.00 Cr
Mar 2025−₹1.00 Cr
Mar 2026₹0.00 Cr

Quarterly Results

₹ Cr
530057 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
9.23
7.62
6.56
4.42
2.44
3
1.5
0.48
8.94
55.36
45.25
6.36
9.29
Expenses
8.64
7.3
6.27
4.56
2.08
2.89
1.37
1.44
8.79
54.75
45.04
6.59
9.36
Operating Profit
0.59
0.32
0.29
−0.14
0.36
0.11
0.13
−0.96
0.15
0.61
0.21
−0.23
−0.07
OPM %
6.39%
4.2%
4.42%
−3.17%
14.75%
3.67%
8.67%
−200%
1.68%
1.1%
0.46%
−3.62%
−0.75%
Other Income
0.01
0.05
0.02
−0.03
0
0
0.01
0.05
0.02
0.01
0.08
0.01
0.37
Interest
0.11
0.11
0.1
0.09
0.09
0.09
0.09
0.08
0.08
0.05
0.09
0.07
0.11
Depreciation
0
0
0
0.01
0
0
0
0
0
0
0
0.01
0.01
PBT
0.49
0.26
0.21
−0.27
0.27
0.02
0.05
−0.99
0.09
0.57
0.2
−0.3
0.18
Tax %
0%
0%
0%
55.56%
0%
0%
0%
1.01%
0%
0%
0%
50%
22.22%
Net Profit
0.49
0.26
0.21
−0.41
0.27
0.02
0.04
−1
0.09
0.56
0.2
−0.45
0.15
EPS (₹)
0.12
0.06
0.05
−0.1
0.07
0
0.01
−0.25
0.02
0.14
0.05
−0.11
0.04

Profit & Loss

₹ Cr
530057 profit and loss, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
3
6
3
10
10
10
18
28
7
116
116
Expenses
0
4
6
3
10
10
10
17
27
8
115
116
Operating Profit
0
0
1
0
0
0
0
1
1
0
1
1
OPM %
—
−9%
9%
−0.8%
−3.6%
0.9%
−0.6%
3.8%
3.9%
−4.9%
0.6%
0.5%
Other Income
0
0
0
0
1
1
1
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
1
1
−1
1
1
Tax %
0%
0%
13%
0%
0%
42%
0%
17%
21%
2%
27%
—
Net Profit
0
0
0
0
0
0
0
1
1
−1
0
0
EPS (₹)
−0.32
−0.08
0.05
−0.11
−0.05
0.02
0.08
0.15
0.14
−0.17
0.1
0.12
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
530057 balance sheet, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.19
4
4
4
4
4
4
4
4
4
4
Reserves
0
0
0
−1
−1
−1
−1
0
1
0
0
Borrowings
0
1
1
1
0
0
6
8
5
9
10
Other Liabilities
0
3
5
6
9
5
7
10
10
4
8
Total Liabilities
1
7
10
11
12
8
16
22
20
16
22
Fixed Assets
0
2
2
2
2
2
2
2
2
2
2
CWIP
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1
5
8
9
10
6
13
20
17
14
20
Total Assets
1
7
10
11
12
8
16
22
20
16
22

Cash Flow

₹ Cr
530057 cash flow, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
−2
0
1
3
−3
2
−1
2
−2
−3
Investing
0
2
0
0
0
0
0
0
0
0
0
Financing
0
0
−1
−1
−3
3
−2
1
−2
2
3
Net Cash Flow
0
0
−1
0
0
0
0
0
0
0
0
Free Cash Flow
0
−2
0
1
3
−3
2
−1
2
−3
−3
CFO/OP
0
668
−15
−4,300
−876
−3,367
−4,117
−124
203
692
−328

Ratios

530057 financial ratios, annual
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
267
287
782
250
231
275
256
151
398
39
Inventory Days
—
215
150
309
38
26
92
55
28
121
11
Days Payable
—
304
319
878
319
154
207
211
116
140
23
Cash Conversion Cycle
—
178
118
213
−32
103
160
99
64
379
27
Working Capital Days
—
332
237
469
109
104
103
50
44
154
7
ROCE %
—
−10%
13%
0%
6%
17%
12%
11%
10%
−3%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vivanza Biosciences insights

56 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 73.90%
  • Promoters 20.02%
  • Others 6.07%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Vivanza Biosciences

What does Vivanza Biosciences Ltd do?
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions
Where is Vivanza Biosciences Ltd (VIVANZA) listed?
Vivanza Biosciences Ltd trades under code 530057 on the BSE.
Which sector does Vivanza Biosciences Ltd belong to?
Vivanza Biosciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Vivanza Biosciences Ltd?
Over the last 52 weeks Vivanza Biosciences Ltd has traded between ₹1.3 and ₹2.72 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd reported a return on equity of 9.38%. Its debt-to-equity ratio is 2.50.

Company Information

Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions

Website vivanzabiosciences.com
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530057.md for Vivanza Biosciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month